Our business
The company's entrepreneurial business model permits independent decision making similar to a family-run enterprise. It relies on strategic collaborations with selected industry partners for late-stage clinical development and commercialization providing independent financing to fund operations, research and development.
At Neurimmune, we focus on the discovery and development of human therapeutic antibodies and other treatment modalities such as small molecules and vectorized antibodies. Partnering and licensing are a key part of Neurimmune's commitment to successfully develop innovative product candidates. Neurimmune has partnered selected programs with Biogen, TVM Capital and Eli Lilly's Chorus unit as well as with Ono Pharmaceutical. In addition, Neurimmune has entered into various research collaborations with academic groups and biotech companies.
Quote
« Neurimmune's entrepreneurial business model permits independent decision making. It relies on strategic collaborations with selected industry partners providing non-dilutive financing to fund our business.»
